By Fineline Cube 
Walvax Biotechnology Co., Ltd (SHE: 300142), a Chinese biopharmaceutical company, has announced that an amendment to its Exclusive Sublicense Agreement with US-based Notitia Biotechnologies, a microbiome-targeted biotherapeutic company. Through this amendment, Walvax secures exclusive rights to develop, manufacture, and commercialize Notitia’s proprietary gut microbiota therapy in mainland China, Hong Kong, and Macau, expanding beyond disease-specific populations to include non-patients focused on chronic disease prevention and health nutrition.
Amended Agreement Details
Originally signed in May 2025, the initial agreement granted Walvax rights for disease-specific populations. The amendment enables a dual-track strategy: “disease treatment intervention” and “chronic disease prevention and control + health nutrition.” This expansion highlights Walvax’s commitment to leveraging Notitia’s technology, licensed from Rutgers University, which integrates core microbiota analysis, targeted microbiota transplantation, and nutritional formulation.
Financial Terms
Under the amendment, Walvax agreed to pay Notitia a licensing fee of USD 1.5 million. Additionally, Walvax is required to pay a continuous royalty of 6.5% of the net sales of the sublicense products, or according to the set minimum royalty. Upon achieving specific milestone events, Walvax will also make milestone payments of up to USD 39 million.-Fineline Info & Tech